Open Search form

Tomer Bronstein

Apply for a Blog

Mar 22, 2022, 12:53 PM

COVID: The end of the beginning

Living alongside coronavirus still requires additional treatments for severe and critical patients, who have the most significant impact on health system failures

Load more

About Me

Dr. Tomer Bronshtein is the Head of Research at Bonus BioGroup, which is developing MesenCure, a cell-based therapy to treat severe corona patients.